Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism

Su,Jun‑Feng; Hu,Xiao‑Hui; Li,Cheng‑Yan

doi:10.3892/etm.2014.2058

Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism

Authors:
- Jun‑Feng Su
- Xiao‑Hui Hu
- Cheng‑Yan Li
View Affiliations

Affiliations: Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Neurology, Jingzhou Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingzhou, Hubei 434020, P.R. China
Published online on: November 10, 2014 https://doi.org/10.3892/etm.2014.2058
Pages: 267-271

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine clopidogrel resistance (CR) in patients with ischemic cerebral infarction and its potential association with a single nucleotide polymorphism (SNP; rs1045642) in the ABCB1 gene. Patients with ischemic cerebral infarction received clopidogrel (75 mg/day) for 7 days and were then subjected to a turbidimetric assay to determine platelet aggregation. Patients were then divided into a CR group and a clopidogrel-sensitive (CS) group. Demographic and clinical data between the two groups were compared. Multivariate logistic regression analysis was performed to determine independent risk factors of CR. PCR products were sequenced to assess ABCB1 rs1045642 SNP genotype and allele frequencies in each group. In total, 303 patients were enrolled in the study; this included 51 CR cases (16.83%) and 252 CS cases (83.17%). Several parameters, including hypertension, diabetes, calcium channel blocker (CCB), β‑receptor blocking agent and proton pump inhibitor use, and creatinine, fasting blood glucose, homocysteine (HCY), high-sensitivity C-reactive protein (hs‑CRP) and triglyceride levels were significantly higher in the CR group than in the CS group. Diabetes, hs‑CRP-increased use of CCBs, and use of β-blockers were found to be independent risk factors for CR. However, ABCB1 gene rs1045642 polymorphism was not found to be an independent risk factor for CR. In conclusion, CR in ischemic stroke patients is associated with several independent risk factors, including diabetes, hs‑CRP‑increased use of CCBs, and use of β-blockers. However, ABCB1 gene rs1045642 polymorphism has no correlation with CR.

View Figures

View References

1	Dupont AG, Gabriel DA and Cohen MG: Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res. 124:6–13. 2009. View Article : Google Scholar : PubMed/NCBI
2	Gurbel PA and Tantry US: Clopidogrel resistance? Thromb Res. 120:311–321. 2007. View Article : Google Scholar
3	Yang R and Wu F: The progress of research on clopidogrel resistance. Int J Intern Med. 36:428–431. 2009.(In Chinese).
4	Ford NF: Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol. 49:506–512. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kolandaivelu K and Bhatt DL: Overcoming ‘resistance’ to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol. 7:461–467. 2010. View Article : Google Scholar : PubMed/NCBI
6	Holmes MV, Perel P, Shah T, Hingorani AD and Casas JP: CYP2C19 genotype, clopidogrel metabolism, platelet function and cardiovascular events: a systematic review and meta-analysis. JAMA. 306:2704–2714. 2011. View Article : Google Scholar : PubMed/NCBI
7	Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N and Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 360:363–375. 2009. View Article : Google Scholar
8	Taubert D, von Beckerath N, Grimberg G, et al: Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 80:486–501. 2006. View Article : Google Scholar : PubMed/NCBI
9	Gros P, Ben Neriah YB, Croop JM and Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 323:728–731. 1986. View Article : Google Scholar : PubMed/NCBI
10	Sakaeda T, Nakamura T and Okumura K: MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 25:1391–1400. 2002. View Article : Google Scholar : PubMed/NCBI
11	Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E and Sabatine MS: Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 376:1312–1319. 2010. View Article : Google Scholar : PubMed/NCBI
12	Neurology Committee of the Chinese Medical Association for cerebrovascular disease diagnosis and treatment guidelines for ischemic stroke. Chinese diagnosis and treatment guidelines for ischemic stroke 2010. Chin J Neurol. 43:146–153. 2010.
13	Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh EE III: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke. 24:35–41. 1993. View Article : Google Scholar : PubMed/NCBI
14	Mega JL, Close SL, Wiviott SD, et al: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 360:354–362. 2009. View Article : Google Scholar
15	Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A and von Beckerath N: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 101:714–719. 2009.PubMed/NCBI
16	Montalescot G, Sideris G, Meuleman C, et al: A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 48:931–938. 2006. View Article : Google Scholar : PubMed/NCBI
17	Lepäntalo A, Virtanen KS, Heikkilä J, Wartiovaara U and Lassila R: Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J. 25:476–483. 2004. View Article : Google Scholar : PubMed/NCBI
18	Hall HM, Banerjee S and McGuire DK: Variability of clopidogrel response in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 8:245–253. 2011. View Article : Google Scholar : PubMed/NCBI
19	Angiolillo DJ and Suryadevara S: Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 23:375–388. 2009. View Article : Google Scholar : PubMed/NCBI
20	Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and elopidogrel treatment. Diabetes. 54:2430–2435. 2005. View Article : Google Scholar : PubMed/NCBI
21	Gurbel PA, Antonino MJ and Tantry US: Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol. 5:989–1004. 2009. View Article : Google Scholar : PubMed/NCBI
22	Kubica A, Kozinski M, Grzesk M, et al: Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis. 32:459–466. 2011. View Article : Google Scholar : PubMed/NCBI
23	Delaney JT, Ramirez1 AH, Bowton E, Pulley JM, Basford MA, Schildcrout JS, Shi Y, Zink R, Oetjens M, Xu H, Cleator JH, Jahangir E, Ritchie MD, Masys DR, Roden DM, Crawford DC and Denny JC: Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther. 91:257–263. 2012. View Article : Google Scholar
24	Yang J, Zhao HD, Tan J, Ding YL, Gu ZQ and Zou JJ: CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients. Pharmazie. 183–186. 2013.PubMed/NCBI
25	Nyírő G, Inczédy-Farkas G, Reményi V, et al: The effect of the CYP 2C19*2 polymorphism on stroke care. Acta Physiol Hung. 99:33–39. 2012. View Article : Google Scholar
26	Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH and Becker RC; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versusclopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 376:1320–1328. 2010. View Article : Google Scholar : PubMed/NCBI